There are currently 117 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.
Anti-Inflammatory Challenge in Schizophrenia
NCT05823532
Recruiting
This research project will explore negative symptoms of schizophrenia, such as motivational deficits, by examining the relationship between inflammation and reward-related brain regions. To accomplish this, we will administer a single infusion of either the anti-inflammatory medication infliximab or placebo (n=10 per group) to patients with high inflammation. This study is important because schizophrenia can be a chronic and debilitating neuropsychiatric disorder and negative symptoms are some... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
04/26/2024
Locations: Grady Memorial Hospital, Atlanta, Georgia +1 locations
Conditions: Schizophrenia
Register for Updates
Network-Targeted Neuromodulation for Nicotine Dependence in Schizophrenia
NCT06389266
Recruiting
The goal of this clinical trial is to compare two active types of transcranial magnetic stimulation in two nicotine-using populations: nicotine-using people with psychosis and nicotine-using people without a diagnosis of a psychotic disorder. The main questions it aims to answer are: Can rTMS change functional connectivity in brain circuits associated with nicotine use? Are those rTMS-induced changes in functional connectivity related to craving? Participants will complete tasks assessing thei... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/24/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Schizophrenia, Nicotine Dependence
Register for Updates
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064
Recruiting
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/23/2024
Locations: Alkermes Investigator Site, Dothan, Alabama +43 locations
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates
Deep rTMS Modulating Insula Synaptic Density and Smoking Behavior in Schizophrenia
NCT05724810
Recruiting
Purpose of the study: Evaluate the effect of deep repetitive transcranial magnetic stimulation (deep rTMS; hereafter abbreviated as "dTMS") on synaptic density measured with positron emission tomography (PET) and the radiotracer [11C]UCB-J. The investigators also seek to link plasticity changes in the regions targeted by the electric field (especially, the insula) to changes in the functioning of insula circuits and behavioral cigarette usage in patients with schizophrenia (SCZ). Importance of... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/23/2024
Locations: Stony Brook University, Stony Brook, New York
Conditions: Schizophrenia, Smoking Cessation, Tobacco Use
Register for Updates
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
NCT06315283
Recruiting
The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia. Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with ora... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
04/19/2024
Locations: Teva Investigational Site 15739, Los Alamitos, California +5 locations
Conditions: Schizophrenia
Register for Updates
Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?
NCT05268809
Recruiting
Wide ranging cognitive deficits are major drivers of functional decline and poor outcomes in people with schizophrenia (SZ) and bipolar disorder (BD). Medications do not target pathophysiological mechanisms thought to underlie these deficits. In the search for interventions targeting underlying cognitive impairment in SZ and BD, we look comprehensively beyond just the brain and to the potential role of dysfunctional systemic metabolism. Disrupted insulin and glucose metabolism are seen in medic... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/19/2024
Locations: San Francisco VA Medical Center, San Francisco, California
Conditions: Schizophrenia, Bipolar Disorder
Register for Updates
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
NCT00004571
Recruiting
The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. Schizophrenia is a brain disorder that results from subtle changes and abnormalities in neurons. These deficits likely occur in localized regions of the brain and may result in widespread, devastating consequences. The neuronal abnormalities are inherited through a complex combination of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Normal Physiology
Register for Updates
PET Scanning in Parkinson s Disease
NCT00024622
Recruiting
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-[F-18] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Parkinson's Disease
Register for Updates
Horyzons: Implementation and Integration in Clinical Practice
NCT06002958
Recruiting
The primary aim of this trial is evaluating the barriers and enablers of implementing a digital intervention with both therapeutic content and social networking, Horyzons, as part of clinical care in first episode psychosis (FEP) clinics in North Carolina. Providers (clinicians and peers support specialists) will be recruited from FEP clinics to assess Horyzons implementation and integration within clinical care at three time points (baseline, 6 months, and 12 months). Further, individuals exper... Read More
Gender:
All
Ages:
Between 16 years and 35 years
Trial Updated:
04/12/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
Register for Updates
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
NCT05859698
Recruiting
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Neurocrine Clinical Site, Sun City, Arizona +26 locations
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Register for Updates
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157
Recruiting
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Neurocrine Clinical Site, Phoenix, Arizona +76 locations
Conditions: Schizophrenia
Register for Updates
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
NCT06336616
Recruiting
The goal of this study is to evaluate the effectiveness of an behavioral activation intervention to increase meaningful activity and community participation for people with serious mental illness. The overall objective of this study is to increase engagement in meaningful activities and community participation. The objectives of the project are as follows: To determine if the intervention leads to increases the frequency and variety of activities. To determine if the intervention leads to incr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Major Depressive Disorder, Schizo Affective Disorder, Schizophrenia, Bipolar Disorder
Register for Updates